FES

Across TCGA pan-cancer cohorts, FES mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FES data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FES mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FES expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where FES mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.704	1.000	.008	14	view →
PDAC	OS	Median	III,IV	0.326	0.829	.004	12	view →
GBM	DFS	Quartile	All	0.587	0.811	.009	5	view →
HNSC	OS	Tertile	IV	0.842	0.609	.038	2	view →
LUAD	DFS	Median	All	0.874	0.507	.016	2	view →
LSCC	DFS	Median	All	0.894	0.976	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FES–CCRCC (DFS)

Open the CCRCC breakdown →